Phase 4
Completed N=100
Envarsus in Delayed Graft Function (E-DGF)
Delayed Graft Function
Source: ClinicalTrials.gov NCT03864926 ↗
Enrolled (actual)
100
Serious AEs
49.0%
Results posted
Jun 2023
Primary outcomePrimary: Number of Days Needed to Recover From Delayed Graft Function (DGF) — 14.0; 15.0 days
◆ Published Evidence
Emerging
3citations · ~2 / year
Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients.
Summary
Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus. It is expected that patients with DGF on Envarsus XR will have more stable tacrolimus levels and facilitate early recover from DGF compared to immediate release tacrolimus.
Linked Publications
-
Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Days Needed to Recover From Delayed Graft Function (DGF) |
14.0; 15.0 | — |
| SECONDARY Number of Tacrolimus or Envarsus XR Dose Adjustments Required During the Period of DGF |
4.0; 3.0 | — |
Eligibility Criteria
Inclusion Criteria
- Willing and able to provide written informed consent
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, at least 18 years of age
- Documented diagnosis of DGF or need for dialysis or had dialysis within the first week of kidney transplant
- Current treatment with tacrolimus based regimen or planned to start tacrolimus based immunosuppressive regimen
- Females of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy.
- A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
Exclusion Criteria
- History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes
- Current use of non-tacrolimus based immunosuppressive regimen or no plan to start tacrolimus based regimen
- Women who are or plan to become pregnant or breast-feeding during the study period
- Not suitable for study participation due to other reasons at the discretion of the investigator
- Major post-surgical complications requiring allograft nephrectomy
- Multi-organ transplant recipients
- Non kidney transplant recipients
Data sourced from ClinicalTrials.gov (NCT03864926) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.